Click here for an archive of Cramer's "Mad Money" recaps.

The four horsemen of tech are riding higher, Jim Cramer told viewers of his "Mad Money" TV show Friday.

Research In Motion ( RIMM), ( AMZN), Apple ( AAPL) and Google ( GOOG), are up 45% on average since he grouped them together, Cramer said.

RIM is up more than 100%, breaking a new record after a monster quarter, Cramer said. Apple is at a new high, and Amazon and Google are very close to their respective highs as well.

While it's good to own these four horsemen, a portfolio needs more than tech, Cramer said. He told viewers that next week they should buy $80 stocks. But not just any $80 stocks, he said, $80 stocks that should go to $120.

In a bull market, Cramer believes that $80 stocks usually reach $100, and most go all the way to $120.

Earlier this year, he recommended stocks based on this $80-to-$120 thesis. But at that time, Cramer said, "the bull market was on the ropes," and the thesis didn't hold up. "The stocks got damaged as the market fell apart."

Now that the bull market is back, it's the "perfect time" to buy Boeing ( BA), Air Products ( APD), Terex ( TEX), Energizer ( ENR), Caterpillar ( CAT) and ConocoPhillips ( COP), the last two of which he owns for his charitable trust, Action Alerts PLUS , Cramer said.

These industrial stocks are where people need to be right now, Cramer said. Buy these stocks not only for their price, but for the sector, which is in a "sweet spot."

Of all the stocks on the list, people should buy Caterpillar and Terex, which Cramer believes are "earth-movers," he said. In third place, Cramer said he likes Conoco. "It should have a great next quarter," he said. "It should go to $120 some time next year."

Masimo to the Max

All week, Cramer said he's been trying to find the an overlooked initial public offering that can double over and over again before it gets tapped out. He believes Masimo ( MASI), which came public on Aug. 8, is it.

Masimo, Cramer said, could be the next Omniture ( OMTR), a "hot" and "totally overlooked" IPO.

When it came public, Masimo was priced low because the market was so bad, but the stocks should go higher. Masimo, he said, makes medical devices that allow for noninvasive measurement of blood oxygenation.

A total of 30% of Masimo's revenue comes from hardware sales, and the other 70% comes from disposable parts needed to operate the hardware, Cramer explained. This means Masimo has "a nice recurring revenue stream." Plus, it's a growing company with patent protection of its products, he said.

Cramer suggested waiting for a pullback before getting into the stock.

As anyone who's watched this show knows, "vanity is one of the most bankable trends out there," Cramer told viewers. Americans would rather look good than feel good and companies that make people look good make investors money.

All for Allergan

Allergan ( AGN), the one-stop-shop for physical enhancement, has been a long-time Cramer favorite.

Although he once thought of it only as a play on silicon breast implants, Cramer now has realized that the stock has much more to offer. It also has its hands in some other medical areas, Cramer said. It makes eye medicines that treat glaucoma, and its Botox product is not only used to get rid of wrinkles, but is also used to treat overactive bladders.

Allergan's Lap-Band, which helps achieve weight loss, is another important product, but Johnson & Johnson ( JNJ) is introducing its own version of the band, Cramer said. However, as the market for these bands is unpenetrated, Cramer believes both companies have room to grow.

Cramer welcomed Allergan CEO David Pyott to the show and asked him about the company's September acquisition of Esprit.

Pyott said that as Allergan is engaged in the phase II and III studies for overactive bladder treatment, they wanted to buy a company that gave them access to that channel.

Further, Pyott said he is not worried about JNJ coming out with its own version of the gastric band because both companies should prosper in the market. "We have less than 1% penetration of this market," he said.

Cramer called Allergan his favorite pharmaceutical company and said AGN is going higher.

Lightning Round

Cramer was bullish on Schering-Plough ( SGP), Synchronoss Technologies ( SNCR), American Eagle Outfitters ( AEO), Bill Barrett ( BBG), XTO Energy ( XTO), Deere ( DE), Bunge ( BG) and Monsanto ( MON).

Cramer was bearish on Hansen Natural ( HANS) and Coldwater Creek ( CWTR).

'Mad Mail'

In his "Mad Mail" segment, Cramer said Boeing ( BA) is down because of a Lehman Brothers downgrade. However, he still believes Boeing is a great story for next three to five years and advised the caller to ignore the negative report.

Responding to another emailer, Cramer said he likes Starent ( STAR) because it's an intellectual property play.

Want more Cramer? Check out Jim's rules and commandments for investing from his latest book by clicking here.

For more of Cramer's insights during the Lightning Round, click here .
At the time of publication, Cramer was long Caterpillar and ConocoPhillips.

Jim Cramer, host of the CNBC television program "Mad Money," is a Markets Commentator for, Inc., and CNBC, and a director and co-founder of All opinions expressed by Mr. Cramer on "Mad Money" are his own and do not reflect the opinions of or its affiliates, or CNBC, NBC UNIVERSAL or their parent company or affiliates. Mr. Cramer's opinions are based upon information he considers to be reliable, but neither, nor CNBC, nor either of their affiliates and/or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. Mr. Cramer's statements are based on his opinions at the time statements are made, and are subject to change without notice. No part of Mr. Cramer's compensation from CNBC or is related to the specific opinions expressed by him on "Mad Money."

None of the information contained in "Mad Money" constitutes a recommendation by Mr. Cramer, or CNBC that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the program. Mr. Cramer's past results are not necessarily indicative of future performance. Neither Mr. Cramer, nor, nor CNBC guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the program. The strategy or investments discussed may fluctuate in price or value and you may get back less than you invested. Before acting on any information contained in the program, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.

Some of the stocks mentioned by Mr. Cramer on "Mad Money" are held in Mr. Cramer's Action Alerts PLUS Portfolio. When that is the case, appropriate disclosure is made on the program and in the "Mad Money" recap available on The Action Alerts PLUS Portfolio contains all of Mr. Cramer's personal investments in publicly-traded equity securities only, and does not include any mutual fund holdings or other institutionally managed assets, private equity investments, or his holdings in, Inc. Since March 2005, the Action Alerts PLUS Portfolio has been held by a Trust, the realized profits from which have been pledged to charity. Mr. Cramer retains full investment discretion with respect to all securities contained in the Trust. Mr. Cramer is subject to certain trading restrictions,

If you liked this article you might like

Qualcomm Nets Wireless Licenses in India

Qualcomm Nets Wireless Licenses in India

SEC Probes Other Deals: Report

SEC Probes Other Deals: Report

Cramer's 'Mad Money' Follow-Up: April 15

Cramer's 'Mad Money' Follow-Up: April 15

Cramer's 'Mad Money' Follow-Up: April 14

Cramer's 'Mad Money' Follow-Up: April 14

Cramer's 'Mad Money' Follow-Up: March 25

Cramer's 'Mad Money' Follow-Up: March 25